# PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

> **NCT00694551** · NA · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Peptide Vaccine
- **DRUG:** Poly IC-LC

## Key facts

- **NCT ID:** NCT00694551
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-02
- **Primary completion:** 2013-02-28
- **Final completion:** 2018-12-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694551, "PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00694551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*